Financial & competing interests disclosure
Irina Savelieva is an advisor/speaker/investigator for sanofi-aventis, Bristol-Myers Squibb, Takeda, Daiichi, Boehringer Ingelheim, Servier, Astra Zeneca, Astellas, Mitsubishi Pharma and Merck. A. John Camm is an advisor/speaker/investigator for Servier, Novartis, sanofi-aventis, Astra Zeneca, Xention, Bristol-Myers Squibb, Menarini, Daiichi, Merck, Boehringer Ingelheim, Medtronic, St Jude Medical, Biotronic and Boston Scientific, and is supported by the British Heart Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.